ORIC PHARMACEUTICALS INC

NASDAQ: ORIC (Oric Pharmaceuticals, Inc.)

Kemas kini terakhir: 5 minit lalu

11.39

0.41 (3.73%)

Penutupan Terdahulu 10.98
Buka 10.91
Jumlah Dagangan 1,266,442
Purata Dagangan (3B) 1,368,470
Modal Pasaran 1,109,263,872
Harga / Buku (P/B) 2.83
Julat 52 Minggu
3.90 (-65%) — 14.93 (31%)
Tarikh Pendapatan 13 Nov 2025
EPS Cair (TTM) -1.88
Jumlah Hutang/Ekuiti (D/E MRQ) 3.97%
Nisbah Semasa (MRQ) 12.00
Aliran Tunai Operasi (OCF TTM) -115.01 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -68.48 M
Pulangan Atas Aset (ROA TTM) -30.87%
Pulangan Atas Ekuiti (ROE TTM) -48.45%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Bercampur
Biotechnology (Global) Bercampur Bercampur
Stok Oric Pharmaceuticals, Inc. Menaik Menurun

AISkor Stockmoo

0.4
Konsensus Penganalisis 4.0
Aktiviti Orang Dalam NA
Volatiliti Harga -2.0
Purata Bergerak Teknikal 0.0
Osilator Teknikal -0.5
Purata 0.38

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
ORIC 1 B - - 2.83
COGT 6 B - - 31.38
CGON 3 B - - 5.27
ADPT 3 B - - 14.73
SANA 1 B - - 6.10
PHAT 1 B - - -

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Value
% Dimiliki oleh Orang Dalam 7.93%
% Dimiliki oleh Institusi 102.70%

Pemilikan

Nama Tarikh Syer Dipegang
Nextech Invest, Ltd. 30 Sep 2025 7,162,637
Nextech Invest Ltd. 31 Dec 2024 5,285,714
Column Group Llc 30 Sep 2025 3,540,777
Julat 52 Minggu
3.90 (-65%) — 14.93 (31%)
Julat Harga Sasaran
15.00 (31%) — 25.00 (119%)
Tinggi 25.00 (Evercore ISI Group, 119.49%) Beli
Median 19.50 (71.20%)
Rendah 15.00 (Oppenheimer, 31.69%) Beli
Purata 19.67 (72.70%)
Jumlah 6 Beli
Harga Purata @ Panggilan 12.03
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Evercore ISI Group 20 Nov 2025 25.00 (119.49%) Beli 11.48
JP Morgan 18 Nov 2025 20.00 (75.59%) Beli 11.90
Citigroup 17 Nov 2025 16.00 (40.47%) Beli 12.06
HC Wainwright & Co. 14 Nov 2025 23.00 (101.93%) Beli 12.25
Oppenheimer 14 Nov 2025 15.00 (31.69%) Beli 12.25
Wells Fargo 14 Nov 2025 19.00 (66.81%) Beli 12.25

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
05 Dec 2025 Pengumuman ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
04 Dec 2025 Pengumuman ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025
03 Dec 2025 Pengumuman ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025
01 Dec 2025 Pengumuman ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025
24 Nov 2025 Pengumuman ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
13 Nov 2025 Pengumuman ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates
13 Nov 2025 Pengumuman ORIC® Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety
07 Nov 2025 Pengumuman ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06 Nov 2025 Pengumuman ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor
04 Nov 2025 Pengumuman ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
27 Oct 2025 Pengumuman ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors
05 Sep 2025 Pengumuman ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda